Triptorelin record · updated 6h ago

Metabolic & appetiteHealing & recoveryGrade B · human evidenceResearch use only

All 5 studies Jump to the evidence Compare

What is Triptorelin used for?

Research peptide discovered via AI researcher. peptide analogue

Primarily researched for · Metabolic & appetite

Development stage

where Triptorelin sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 37 registered trials. It describes the research record, not a recommendation.

Identity

NameTriptorelin

Chain length—

Molecular weight1,311.4 Da

FormulaC64H82N18O13

Structure typeNot established

ClassHealing

Research levelWell Studied

Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 25074470. No verified residue count for this compound.

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 8, 2026. How this works →

Research stats

Total studies5

Human / animal / cellular3 / 2 / 0

Highest trial phase—

Years covered2025–2026

Latest study2mo ago

Publication history

20252026

Research funding

20 NIH projects · $1.4M awarded · through FY2018

Public grants naming this compound. Funding is interest, not evidence.

Safety signals

FAERS reports2,022

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 5 Semantic Scholar UniProt

Study register

5 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Treatment Outcomes in 84 Male Children with Accelerated Pubertal Progression: A Comparative Analysis ofGnRHa, Combined GH Therapy and Aromatase Inhibitor FindingΔH/y of combination therapy was 8.49 ± 3.22 cm/y, GnRHa was 6.73 ± 1.95 cm/y, and AI was 7.75 ± 1.92 cm/y, P < 0.01.	Human	2026	Full text read0.80
Perceived Stress During Gender-Affirming Hormone Therapy: A Comparative Study of Feminizing and Masculinizing Hormone Therapy in an International Multicenter Prospective Cohort FindingNo significant changes in perceived stress were observed after 3 months (-1.0, p = 0.21).	Human	2025	Full text read0.80
GnRH Agonist Triptorelin Induces Hepatic Fibrosis via Sex-Specific Oxidative and Inflammatory Responses in Adolescent Rats FindingNot reported in abstract.	Animal	2025	Full text read0.70
Reproductive Axis Recovery Post Ovarian Stimulation and Gonadotropin Releasing Hormone Agonist (GnRH-a) Trigger, Observational Case Series FindingOvulation was delayed to cycle day 21, compared to the predicted cycle day 14.	Human	2025	Full text read0.80
Pubertal Triptorelin Exposure Alters Hypothalamic Reproductive–Metabolic Integration in a Sex-Specific Manner FindingNot reported in abstract.	Animal	2026	Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Triptorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Triptorelin is discussed should be drawn from it.